Business
CG Oncology Announces New Board Member and Board Transition
- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology,
About this update from Cg Oncology, Inc.
[{"type":"text","content":"- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the appointment of Christina Rossi to its Board of Directors. Additionally, Simone Song, Senior Partner, ORI Capital, has resigned from the Board effective November 22, 2025. “We are at a critical juncture in CG Oncology’s history with our recent BLA initiation for cretostimogene. Now we are laying the foundation for a successful launch upon FDA approval, which includes adding Christy to our Board of Directors. Christy has a proven track record for building high-performing commercial organizations, launching new medicines, and delivering impactful programs to HCPs and most importantly to patients. We are positioned to address the broadest range of NMIBC patients to date, thanks to the hard work and dedication of our employees and Board over the years. I want to especially thank Simone for more than a decade of service on our Board and her many contributions to our strategy and direction,” said Arthur Kuan, Chairman and Chief Executive Officer of CG Oncology. Ms. Rossi has more than 25 years of global pharmaceutical and biotechnology experience. Most recently, she served as Chief Operating Officer of Blueprint Medicines from 2022 until its acquisition by Sanofi in 2025. Previously, she served as Chief Commercial Officer and has overseen the commercial launches of Blueprint therapies across multiple indications and geographies, including the creation of commercial infrastructure and successful market access efforts in the U.S. and Europe. Prior to joining Blueprint Medicines, she served as the Multiple Sclerosis (MS) Business Unit Head, North America, at Sanofi Genzyme. In this role, she oversaw all aspects of the financial performance of Sanofi Genzyme’s MS franchise and increased market share for existing products, led the launch of new therapies and optimized operations to accelerate patient access. Previously, Ms. Rossi served as Vice President, MS Sales, and Vice President, MS Patient and Provider Services, at Sanofi Genzyme. Prior to joining Sanofi Genzyme, she held ...